Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study

BACKGROUND: To verify the long-term (24-week) efficacy, safety, and tolerability of fremanezumab in real-life patients with high-frequency episodic migraine (HFEM: ≥ 8 days/month) or chronic migraine (CM: ≥ 15 days/month), and multiple preventive treatment failures. METHODS: This is a prospective, c...

Descripción completa

Detalles Bibliográficos
Autores principales: Barbanti, Piero, Egeo, Gabriella, Aurilia, Cinzia, Torelli, Paola, Finocchi, Cinzia, d’Onofrio, Florindo, d’Onofrio, Luigi, Rao, Renata, Messina, Stefano, Di Clemente, Laura, Ranieri, Angelo, Autunno, Massimo, Sette, Giuliano, Colombo, Bruno, Carnevale, Antonio, Aguggia, Marco, Tasillo, Miriam, Zoroddu, Francesco, Frediani, Fabio, Filippi, Massimo, Tomino, Carlo, Proietti, Stefania, Bonassi, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035286/
https://www.ncbi.nlm.nih.gov/pubmed/36949388
http://dx.doi.org/10.1186/s10194-023-01561-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035286/
https://www.ncbi.nlm.nih.gov/pubmed/36949388
http://dx.doi.org/10.1186/s10194-023-01561-w

Ejemplares similares